The Company’s near-term plans are to submit market applications in multiple countries for the Company's anti-viral drugs and complete Phase I safety, immunology & efficacy studies of the HCV vaccine in humans, thus creating value by achieving major developmental milestones in the next 18-24 months – revenue generation from the sales of anti-viral drugs, and proof in humans that VLP vaccine immunization leads to development of neutralizing antibodies that attack the HCV virus and prevent infection. Based on our ability to attract a corporate partner and/or raise money in the private and public markets,


Cyplasin Biomedical will continue to advance the development of other anti-viral pipeline products and we plan to begin Phase II efficacy studies of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection. An antibody product derived from healthy volunteers administered VLP vaccine inoculations will be evaluated as a passive immunotherapy product in patients undergoing liver transplantation to prevent or significantly delay the liver graft re-infection by the hepatitis C virus.